References of "Reginster, Jean-Yves"
     in
Bookmark and Share    
Full Text
Peer Reviewed
See detailPrévalence de la sarcopénie : impact de l'utilisation de différentes valeurs seuils de diagnostic
Beaudart, Charlotte ULg; Reginster, Jean-Yves ULg; Slomian, Justine ULg et al

in Cahiers de l'Année Gérontologique (Les) (2014), 2(23), 513-75

Detailed reference viewed: 4 (2 ULg)
Full Text
Peer Reviewed
See detailValidation des paramètres de marche par un système accélérométrique (Locométrix) à l’aide d’un système opto-électronique 3D (Coda Motion)
GILLAIN, Sophie ULg; Schwartz, C; Dramé, M et al

in Cahiers de l'Année Gérontologique (Les) (2014), 2(23), 724-73

Detailed reference viewed: 10 (4 ULg)
Full Text
Peer Reviewed
See detailEvaluation du nombre de résidents en maison de retraite médicalisée bénéficiant d'une supplémentation en vitamine D
Buckinx, Fanny ULg; Reginster, Jean-Yves ULg; Cavalier, Etienne ULg et al

in Cahiers de l'Année Gérontologique (Les) (2014), 2(23), 207-63

Detailed reference viewed: 19 (8 ULg)
Full Text
Peer Reviewed
See detailL'ostéoporose demeure une maladie fatale : la vigilance reste de mise
Reginster, Jean-Yves ULg

in Medicographia (2014), 36(2), 141-142

Detailed reference viewed: 18 (2 ULg)
Full Text
Peer Reviewed
See detailDon't drop the guard: osteoporosis is still a fatal disease !
Reginster, Jean-Yves ULg

in Medicographia (2014), 36(2), 139-140

Detailed reference viewed: 17 (2 ULg)
Full Text
Peer Reviewed
See detailEfficacy and safety of currently marketed anti-osteoporosis medications
Reginster, Jean-Yves ULg; NEUPREZ, Audrey ULg; Dardenne, Nadia ULg et al

in Best Practice & Research. Clinical Endocrinology & Metabolism (2014), 28

During the past 2 decades, many interventions were proven effective in the management of postmenopausal osteoporosis. The objective of an anti-osteoporosis treatment is to reduce fracture rates, ideally ... [more ▼]

During the past 2 decades, many interventions were proven effective in the management of postmenopausal osteoporosis. The objective of an anti-osteoporosis treatment is to reduce fracture rates, ideally at all skeletal sites (i.e. spine, hip, and other non-spine). The armamentarium against osteoporosis includes anti-resorptive agents (i.e. bisphosphonates, selective estrogen receptor modulators and denosumab), bone-forming agents (i.e. peptides from the parathyroid hormone family) and one agent with a dual mechanism of action (i.e. strontium ranelate). All these medications combine anti-fracture efficacy with a reasonable benefit/risk profile. However, the choice of a particular chemical entity, in one individual patient is based on the knowledge and expertise of the physician. Prioritization of drugs should be based on the individual profile of the patient, the severity of osteoporosis and the specific contraindications, warnings and precautions of use of the various available medications. [less ▲]

Detailed reference viewed: 32 (13 ULg)
Full Text
Peer Reviewed
See detailGaucher Disease and Bone Manifestations
Marcucci, Gemma; Zimran, Ari; Bembi, Bruno et al

in Calcified tissue international (2014), 95(6), 477-494

Gaucher disease is a relatively rare metabolic disease caused by the inherited deficiency of the lysosomal enzyme glucocerebrosidase. Gaucher disease affects multiple organs, among which is the skeleton ... [more ▼]

Gaucher disease is a relatively rare metabolic disease caused by the inherited deficiency of the lysosomal enzyme glucocerebrosidase. Gaucher disease affects multiple organs, among which is the skeleton. Bone involvement occurs frequently in Gaucher disease, and is one of its most debilitating features, reducing the quality of life of patients. Bone status is an important consideration for treatment to ameliorate symptoms and reduce the risk of irreversible complications. We have conducted a systematic review of all the various aspects of Gaucher disease, focusing on different skeletal manifestations, pathophysiology of bone alterations, clinical symptoms, and current diagnostic and therapeutic approaches. [less ▲]

Detailed reference viewed: 12 (1 ULg)
Full Text
Peer Reviewed
See detailThe effects of vitamin D on skeletal muscle strength, muscle mass and muscle power: a systematic review and meta-analysis of randomized controlled trials.
Beaudart, Charlotte ULg; Buckinx, Fanny ULg; Rabenda, Véronique ULg et al

in The Journal of clinical endocrinology and metabolism (2014), 99(11), 4336-4345

Context There is growing evidence that vitamin D plays a role on several tissues including skeletal muscle. Objective To summarize with a meta-analyse the effects of vitamin D supplementation on muscle ... [more ▼]

Context There is growing evidence that vitamin D plays a role on several tissues including skeletal muscle. Objective To summarize with a meta-analyse the effects of vitamin D supplementation on muscle function. Data sources A systematic research of randomized controlled trials, performed between 1966 and January 2014 has been conducted on Medline, Cochrane Database of Systematics Reviews, Cochrane Central Register of Controlled and completed by a manual review of the literature and congressional abstracts. Study selection All forms and doses of vitamin D supplementation, with or without calcium supplementation, compared with placebo or control were included. Out of the 225 potentially relevant articles, 30 randomized controlled trials involving 5615 individuals (mean age: 61.1 years) met the inclusion criteria. Data extraction Data were extracted by two independent reviewers. Data synthesis Results revealed a small but significant positive effect of vitamin D supplementation on global muscle strength with a standardized mean difference (SMD) of 0.17 (p=0.02). No significant effect was found on muscle mass (SMD 0.058; p=0.52) or muscle power (SMD 0.057; p=0.657). Results on muscle strength were significantly more important with people who presented a 25-hydroxyvitamin D level <30 nmol/L. Supplementation seems also more effective on people aged 65 years or older compared to younger subjects (SMD 0.25; 95% CI 0.01 to 0.48 versus SMD 0.03; 95% CI -0.08 to 0.14). Conclusions Vitamin D supplementation has a small positive impact on muscle strength but additional studies are needed to define optimal treatment modalities, including dose, mode of administration and duration. [less ▲]

Detailed reference viewed: 40 (18 ULg)
Full Text
Peer Reviewed
See detailPréface
Reginster, Jean-Yves ULg

in Best Practice & Research. Clinical Endocrinology & Metabolism (2014), 28

Detailed reference viewed: 14 (5 ULg)
Full Text
Peer Reviewed
See detailMonitoring of osteoporosis therapy
Bruyère, Olivier ULg; Reginster, Jean-Yves ULg

in Best Practice & Research. Clinical Endocrinology & Metabolism (2014), 28

Over the past two decades, major advances have been made in the number and range of agents available for the treatment of osteoporosis, all with proven anti-fracture efficacy. Unfortunately, compliance ... [more ▼]

Over the past two decades, major advances have been made in the number and range of agents available for the treatment of osteoporosis, all with proven anti-fracture efficacy. Unfortunately, compliance with these treatments is not optimal, and a number of patients could be considered as non-responders. Consequently, monitoring anti-osteoporotic therapy could be part of successful osteoporosis management. Currently, no formal well-accepted clinical practice guidelines are available for monitoring anti-osteoporosis therapies. Changes in bone mineral density and bone turnover markers, while on therapy, have potential value in monitoring treatment but their assessment and, consequently, their benefits could be limited by metrological and clinical issues. Moreover, their effectiveness is probably drug dependant. Recommendation for the standardisation of the methodology when analysing the potential relevance of tools for the monitoring of osteoporosis therapy is needed. [less ▲]

Detailed reference viewed: 21 (9 ULg)
Full Text
Peer Reviewed
See detailSafety and tolerability of odanacatib therapy in postmenopausal women with osteoporosis: results from the phase III long-term odanacatib fracture trial
Papapoulos, S; McClung, MR; Langdahl, B et al

in Osteoporosis International (2014), 25(5), 604-605

Detailed reference viewed: 9 (1 ULg)
Full Text
Peer Reviewed
See detailOdanacatib anti-fracture efficacy and safety in postmenopausal women with osteoporosis: results from the phase III long-term odanacatib fracture trial
McClung, MR; Langdahl, B; Papapoulos, S et al

in Osteoporosis International (2014), 25(5), 573-575

Detailed reference viewed: 11 (1 ULg)
Full Text
Peer Reviewed
See detailAlgorithm for the symptomatic and structural treatment of osteoarthritis
Reginster, Jean-Yves ULg

in Osteoporosis International (2014), 25(5), 564

Detailed reference viewed: 1 (1 ULg)
Full Text
Peer Reviewed
See detailOdanacatib anti-fracture efficacy and safety in postmenopausal women with osteoporosis: results from the phase III long-term odanacatib fracture trial
McClung, MR; Langdahl, B; Papapoulos, S et al

in Arthritis and Rheumatism (2014), 66(11), 987

Detailed reference viewed: 7 (0 ULg)
Full Text
Peer Reviewed
See detailPercentage of women achieving non-osteoporotic BMD T-scores at the spine and hip over 8 years of denosumab treatment
Ferrari, S; Libanati, C; Lin, CJF et al

in Arthritis and Rheumatism (2014), 66(11), 986-987

Detailed reference viewed: 9 (4 ULg)
Full Text
Peer Reviewed
See detailAssociation between lean mass and hip bone mineral density
Beaudart, Charlotte ULg; Reginster, Jean-Yves ULg; Slomian, Justine ULg et al

in Arthritis and Rheumatism (2014), 66(11), 95

Detailed reference viewed: 6 (3 ULg)
Full Text
Peer Reviewed
See detailGoal-directed treatment of osteoporosis in Europe.
Kanis, J. A.; McCloskey, E.; Branco, J. et al

in Osteoporosis international : a journal established as result of cooperation between the European Foundation for Osteoporosis and the National Osteoporosis Foundation of the USA (2014), 25(11), 2533-2543

Despite the proven predictive ability of bone mineral density, Fracture Risk Assessment Tool (FRAX(R)), bone turnover markers, and fracture for osteoporotic fracture, their use as targets for treatment of ... [more ▼]

Despite the proven predictive ability of bone mineral density, Fracture Risk Assessment Tool (FRAX(R)), bone turnover markers, and fracture for osteoporotic fracture, their use as targets for treatment of osteoporosis is limited. INTRODUCTION: Treat-to-target is a strategy applied in several fields of medicine and has recently become an area of interest in the management of osteoporosis. Its role in this setting remains controversial. This article was prepared following a European Society for Clinical and Economic Aspects of Osteoporosis and Osteoarthritis (ESCEO) working group meeting convened under the auspices of the International Osteoporosis Foundation (IOF) to discuss the feasibility of applying such a strategy in osteoporosis in Europe. METHODS: Potential targets range from the absence of an incident fracture to fixed levels of bone mineral density (BMD), a desired FRAX(R) score, a specified level of bone turnover markers or indeed changes in any one or a combination of these parameters. RESULTS: Despite the proven predictive ability of all of these variables for fracture (particularly BMD and FRAX), their use as targets remains limited due to low sensitivity, the influence of confounders and current lack of evidence that targets can be consistently reached. CONCLUSION: ESCEO considers that it is not currently feasible to apply a treat-to-target strategy in osteoporosis, though it did identify a need to continue to improve the targeting of treatment to those at higher risk (target-to-treat strategy) and a number of issues for the research agenda. These include international consensus on intervention thresholds and definition of treatment failure, further exploration of the relationship between fracture and BMD, and FRAX and treatment efficacy and investigation of the potential of short-term targets to improve adherence. [less ▲]

Detailed reference viewed: 16 (9 ULg)
Full Text
Peer Reviewed
See detailErratum to: Management of osteoporosis of the oldest old
Rizzoli, R; Branco, J; Brandi, ML et al

in Osteoporosis International (2014), 25

Detailed reference viewed: 13 (2 ULg)
Full Text
Peer Reviewed
See detailManagement of osteoporosis of the oldest old.
Rizzoli, R.; Branco, J.; Brandi, M.-L. et al

in Osteoporosis international : a journal established as result of cooperation between the European Foundation for Osteoporosis and the National Osteoporosis Foundation of the USA (2014), 25

This consensus article reviews the diagnosis and treatment of osteoporosis in geriatric populations. Specifically, it reviews the risk assessment and intervention thresholds, the impact of nutritional ... [more ▼]

This consensus article reviews the diagnosis and treatment of osteoporosis in geriatric populations. Specifically, it reviews the risk assessment and intervention thresholds, the impact of nutritional deficiencies, fall prevention strategies, pharmacological treatments and their safety considerations, the risks of sub-optimal treatment adherence and strategies for its improvement. INTRODUCTION: This consensus article reviews the therapeutic strategies and management options for the treatment of osteoporosis of the oldest old. This vulnerable segment (persons over 80 years of age) stands to gain substantially from effective anti-osteoporosis treatment, but the under-prescription of these treatments is frequent. METHODS: This report is the result of an ESCEO (European Society for Clinical and Economic Aspects of Osteoporosis and Osteoarthritis) expert working group, which explores some of the reasons for this and presents the arguments to counter these beliefs. The risk assessment of older individuals is briefly reviewed along with the differences between some intervention guidelines. The current evidence on the impact of nutritional deficiencies (i.e. calcium, protein and vitamin D) is presented, as are strategies to prevent falls. One possible reason for the under-prescription of pharmacological treatments for osteoporosis in the oldest old is the perception that anti-fracture efficacy requires long-term treatment. However, a review of the data shows convincing anti-fracture efficacy already by 12 months. RESULTS: The safety profiles of these pharmacological agents are generally satisfactory in this patient segment provided a few precautions are followed. CONCLUSION: These patients should be considered for particular consultation/follow-up procedures in the effort to convince on the benefits of treatment and to allay fears of adverse drug reactions, since poor adherence is a major problem for the success of a strategy for osteoporosis and limits cost-effectiveness. [less ▲]

Detailed reference viewed: 11 (4 ULg)
Full Text
Peer Reviewed
See detailOpportunity and challenges of eHealth and mHealth for patients and caregivers
Slomian, Justine ULg; Reginster, Jean-Yves ULg; Ethgen, Olivier ULg et al

in Austin Journal of Public Health and Epidemiology (2014), 1(2), 3-5

Detailed reference viewed: 11 (4 ULg)